How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,635 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13961. Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

less than 1.2 mg/dL SGOT less than 60 IU/L Renal: Creatinine less than 1.35 mg/dL Cardiovascular: LVEF normal by echocardiography or MUGA Other: No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No serious uncontrolled medical condition No uncontrolled psychiatric or addictive disorders Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified (...) cancer stage IIIC breast cancer inflammatory breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Inflammatory Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Cyclophosphamide Fluorouracil Docetaxel Epirubicin Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents

2001 Clinical Trials

13962. BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy

information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed recurrent metastatic adenocarcinoma of the stomach or gastroesophageal junction No squamous cell or sarcomatous elements in tumor Previously treated with 1 prior fluoropyrimidine and/or platinum based chemotherapy regimen for metastatic disease OR Recurrent disease within 6 months of completing adjuvant (...) esophageal cancer recurrent esophageal cancer adenocarcinoma of the stomach adenocarcinoma of the esophagus Additional relevant MeSH terms: Layout table for MeSH terms Adenocarcinoma Stomach Neoplasms Esophageal Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Head and Neck Neoplasms Esophageal Diseases

2001 Clinical Trials

13963. BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy

Sponsor: Bristol-Myers Squibb Collaborator: National Cancer Institute (NCI) Information provided by: Bristol-Myers Squibb Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have metastatic stomach cancer previously treated with chemotherapy. Condition or disease Intervention/treatment Phase (...) table for MeSH terms Adenocarcinoma Stomach Neoplasms Esophageal Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Head and Neck Neoplasms Esophageal Diseases

2001 Clinical Trials

13964. Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia

to treat anemia in patients who have received chemotherapy and/or radiation therapy for cervical cancer. Randomized phase III trial to study the effectiveness of epoetin alfa in treating anemia in patients who have cervical cancer. Condition or disease Intervention/treatment Phase Anemia Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Cervical Squamous Cell Carcinoma Drug Toxicity Radiation Toxicity Stage IIB Cervical Cancer Stage III Cervical Cancer Stage IVA Cervical Cancer Radiation (...) : January 27, 2003 Last Update Posted: August 9, 2017 Last Verified: August 2017 Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Adenocarcinoma Anemia Uterine Cervical Neoplasms Carcinoma, Adenosquamous Drug-Related Side Effects and Adverse Reactions Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Hematologic Diseases Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site

2001 Clinical Trials

13965. Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan

No active or uncontrolled infection No evidence of other serious illness No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or noninvasive carcinomas Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: No concurrent sargramostim (GM-CSF) At least 4 weeks since prior chemotherapy No more than 1 prior chemotherapy regimen for advanced colorectal cancer Prior adjuvant (...) they stop growing or die. Combining more than one drug may kill more tumor cells. Condition or disease Intervention/treatment Phase Colorectal Cancer Drug: FOLFOX regimen Drug: fluorouracil Drug: leucovorin calcium Drug: oxaliplatin Phase 2 Detailed Description: OBJECTIVES: I. Determine the tumor response rate in patients treated with oxaliplatin, fluorouracil, and leucovorin calcium for metastatic colorectal cancer previously treated with irinotecan. II. Determine the time to tumor progression, time

2001 Clinical Trials

13966. BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

arrhythmia Other: Not pregnant or nursing Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer in remission No prior severe hypersensitivity reaction to drugs containing Cremophor EL No active or uncontrolled infection No severe psychiatric disorders PRIOR CONCURRENT THERAPY: Biologic therapy: No prior neoadjuvant, adjuvant, or primary (...) by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced pancreatic cancer. Condition or disease Intervention/treatment Phase Pancreatic Cancer Drug: ixabepilone Phase 2 Detailed Description: OBJECTIVES: Determine the 6-month survival rate and time

2001 Clinical Trials

13967. Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer

recurrent renal cell cancer Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma, Renal Cell Kidney Neoplasms Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases Alvocidib Antineoplastic Agents Growth Inhibitors Growth Substances Physiological Effects of Drugs Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action (...) adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer in complete remission No history of allergic reactions to compounds of similar chemical or biologic composition to flavopiridol (e.g., staurosporine, deschloroflavopiridol, or butyrolactone I) No other uncontrolled illness (e.g., diabetes mellitus) No ongoing or active infection No psychiatric illness or social situation that would preclude study compliance Not pregnant or nursing Negative

2001 Clinical Trials

13968. Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer

failure No serious uncontrolled cardiac arrhythmia Other: No active or uncontrolled infection No evidence of other serious illness No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or noninvasive carcinomas Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent sargramostim (GM-CSF) Chemotherapy: See Disease Characteristics At least 4 weeks (...) : January 27, 2003 Last Update Posted : December 7, 2016 Sponsor: Alliance for Clinical Trials in Oncology Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Alliance for Clinical Trials in Oncology Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells. PURPOSE: Phase II trial

2001 Clinical Trials

13969. Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

: May 27, 2013 Last Verified: May 2004 Keywords provided by Gynecologic Oncology Group: stage III cervical cancer recurrent cervical cancer stage IVB cervical cancer stage IVA cervical cancer cervical squamous cell carcinoma Additional relevant MeSH terms: Layout table for MeSH terms Uterine Cervical Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female Capecitabine Antimetabolites (...) Group Collaborator: National Cancer Institute (NCI) Information provided by: Gynecologic Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have advanced, persistent, or recurrent cervical cancer. Condition or disease Intervention/treatment Phase Cervical Cancer Drug

2001 Clinical Trials

13970. PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically or cytologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus Tumors of the gastroesophageal (...) carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, basal cell skin cancer, or squamous cell carcinoma of the head and neck within the past 3 years No concurrent malignancies at other sites No psychiatric or other disorder that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent anticancer biologic response modifiers or immunotherapy No concurrent sargramostim

2001 Clinical Trials

13971. Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen

5 years except effectively treated squamous cell or basal cell skin cancer, surgically treated carcinoma in situ of the cervix, or surgically treated lobular carcinoma in situ of the ipsilateral or contralateral breast No nonmalignant systemic disease that would preclude study participation No psychiatric or addictive disorder that would preclude informed consent Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior adjuvant chemotherapy allowed (...) a complete axillary dissection Previously resected margins must be clear of invasive tumor and ductal carcinoma in situ Currently disease free Previously treated with tamoxifen for 57-66 months Completed tamoxifen within the past 180 days No bilateral malignancy or mass in the opposite breast suspicious for malignancy unless biopsy proven negative No local, regional, or distant recurrence of disease or second primary breast malignancy (including contralateral breast cancer) No advanced disease at time

2001 Clinical Trials

13972. S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer

1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) SGOT or SGPT no greater than 2 times ULN Renal: Creatinine no greater than ULN Cardiovascular: No congestive heart failure or angina pectoris LVEF greater than lower limit of normal Other: No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix HIV negative Not pregnant or nursing Fertile patients must (...) Verified: January 2013 Keywords provided by Southwest Oncology Group: stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer stage IIIC breast cancer inflammatory breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel Albumin-Bound Paclitaxel Cyclophosphamide Doxorubicin Liposomal doxorubicin Lenograstim Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators

2001 Clinical Trials

13973. BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Other: No other malignancy within the past 5 years except adequately treated squamous cell or basal cell skin cancer, any carcinoma in situ, or stage I or II cancer in complete remission No other concurrent significant active illness that would preclude study participation Recovered from major infections Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: At least 28 days since prior biologic therapy and recovered No more than 1 prior biologic (non-cytotoxic (...) : Southwest Oncology Group Collaborator: National Cancer Institute (NCI) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have prostate cancer that has not responded to hormone therapy. Condition or disease Intervention/treatment Phase

2001 Clinical Trials

13974. DX-8951f in Treating Patients With Metastatic Stomach Cancer

adenocarcinoma Lymph node involvement and/or distant metastasis No squamous cell carcinoma, small cell carcinoma, lymphoma, or leiomyosarcoma of the stomach Measurable disease with indicator lesions outside the field of prior radiotherapy At least 20 mm by conventional scan OR At least 10 mm by spiral CT scan Nonmeasurable lesions include the following: Primary tumor Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonitis Cystic (...) Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have metastatic stomach cancer. Condition or disease Intervention/treatment Phase Esophageal Cancer Gastric Cancer Drug: exatecan mesylate Phase 2 Detailed Description: OBJECTIVES: Determine the objective response rate of patients with previously untreated

2001 Clinical Trials

13975. S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat

60 mL/min Other: Magnesium normal (magnesium supplement allowed) No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission HIV negative Not pregnant or nursing Patients must use effective barrier contraception and prevent bodily fluid transmission during and for 28 days after Ad5CMV-p53 gene administration PRIOR CONCURRENT THERAPY: Biologic therapy (...) to damage tumor cells. Combining chemotherapy and radiation therapy with the p53 gene may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy plus surgery followed by cisplatin and radiation therapy in treating patients who have newly diagnosed resectable stage III or stage IV cancer of the mouth or throat. Condition or disease Intervention/treatment Phase Head and Neck Cancer Biological: Ad5CMV-p53 gene Drug: cisplatin Procedure: conventional surgery Radiation

2001 Clinical Trials

13976. Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer

: ECOG 0-2 Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No history of congestive heart failure or thromboembolic events No uncontrolled hypertension, active thromboembolic disease, or myocardial infarction within the past 3 months Pulmonary: No history of pulmonary edema Other: No other malignancy within the past 3 years except curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer No feeding tube (...) First Posted: July 28, 2003 Last Update Posted: August 10, 2018 Last Verified: August 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by Wake Forest University Health Sciences: untreated metastatic squamous neck cancer with occult primary metastatic squamous neck cancer with occult primary squamous cell carcinoma stage I squamous cell carcinoma of the lip and oral cavity stage I basal cell

2000 Clinical Trials

13977. S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat

be scheduled to receive high-dose radiotherapy Not concurrently receiving or planning to receive treatment on any other Southwest Oncology Group protocol PATIENT CHARACTERISTICS: Age: 18 to 90 Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer (...) or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 90 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Newly diagnosed, previously untreated squamous cell cancer of the oral cavity or oropharynx (T1-T4, any N, M0) Must

2000 Clinical Trials

13978. S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer

No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer in complete remission No active or uncontrolled infection PRIOR CONCURRENT THERAPY: Biologic therapy: No prior immunotherapy for this cancer Chemotherapy: No prior chemotherapy for this cancer Endocrine therapy: Not specified Radiotherapy: No prior pelvic radiation for this cancer Surgery: See Disease (...) Adenocarcinoma Large pelvic mass and/or bulky abdominal disease and/or malignant pleural effusion Pleural effusion only for stage IV (parenchymal, liver, lung, or other distant metastases not allowed) No borderline or low-malignant potential tumors Optimal cytoreduction clinically deemed unlikely CA 125 at least 70 units/mL PATIENT CHARACTERISTICS: Age: Not specified Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,500/mm^3 Platelet count at least

2001 Clinical Trials

13979. Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer

( Registry Identifier: PDQ (Physician Data Query) ) EU-20036 First Posted: June 5, 2003 Last Update Posted: August 7, 2013 Last Verified: October 2002 Keywords provided by National Cancer Institute (NCI): stage III cervical cancer stage IIB cervical cancer stage IVA cervical cancer cervical squamous cell carcinoma cervical adenocarcinoma cervical adenosquamous cell carcinoma Additional relevant MeSH terms: Layout table for MeSH terms Uterine Cervical Neoplasms Fever Uterine Neoplasms Genital Neoplasms (...) (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage IIB-IVA carcinoma of the cervix Adenocarcinoma Squamous cell carcinoma Mixed cell histology No small cell anaplastic histology No para-aortic lymph node involvement No indication for para-aortic radiotherapy No distant metastases No CNS disease PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-2 Life expectancy: More

2001 Clinical Trials

13980. Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer

Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN) SGOT no greater than 2 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: LVEF normal by echocardiography or MUGA Other: Not pregnant or nursing Fertile patients must use effective contraception No other serious uncontrolled illnesses No uncontrolled psychiatric or addictive disorders No other concurrent or prior malignancy within the past 5 years except adequately treated basal or squamous cell skin (...) Information provided by (Responsible Party): European Organisation for Research and Treatment of Cancer - EORTC Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells and shrink tumors so they can be removed during surgery. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy before surgery in treating women

2001 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>